4D Molecular Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
FDMT$12.48+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Comprehensive Loss
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Net loss | $(100,837) | $(107,494) |
| Other comprehensive loss: | ||
| Net unrealized gain (loss) on marketable securities | 1,212 | (773) |
| Total comprehensive loss | $(99,625) | $(108,267) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.